Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bruker Corporation(BRKR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BRKR
11/10/2026: BRKR (2-star) is currently NOT-A-BUY. Pass it for now.
Bruker Corporation is a specialized provider of high-performance scientific instrumentation, serving the life science research and clinical diagnostics markets. The company maintains a leading position in niche areas like NMR and mass spectrometry, with recent acquisitions in spatial biology further expanding its growth potential. While its high-end product portfolio supports strong margins and technical differentiation, the company faces inherent risks from research budget cycles, integration challenges, and intense competition from larger life science conglomerates. Bruker may best suit growth-oriented investors with a long-term outlook, as it prioritizes innovation and strategic M&A over dividends. Monitoring R&D funding trends and acquisition performance remains critical for investors.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Bruker's focus on high-growth areas like proteomics and spatial biology aligns with long-term capital appreciation goals. |
| Momentum investor | Mixed fit | Momentum fit is conditional on a positive Upturn signal in research and clinical spending trends. |
| Value investor | Mixed fit | Valuation varies significantly with the cycle of high-end R&D spending and M&A integration success. |
| Dividend investor | Weak fit | Bruker historically prioritizes reinvestment over consistent dividend distributions to shareholders. |
| Low-risk investor | Weak fit | Exposure to R&D budget volatility and the complexities of high-tech instrumentation creates moderate risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is sensitive to shifts in research funding and broader market sentiment regarding life science growth. |
| Valuation risk | Medium | As a growth-oriented instrument company, valuations often command a premium that requires steady execution to maintain. |
| Competition risk (Instrumentation conglomerate competition) | High | Larger competitors like TMO and DHR have significantly more scale to bundle products and pressure pricing. |
| Business quality | Strong | The company's strong brand and specialized technology provide a meaningful competitive moat. |
| Dividend income | Low | Income-focused investors will likely find better alternatives given the company's growth-first capital policy. |
| Execution risk | Medium | Successfully integrating acquired companies into a decentralized organizational model is critical to long-term success. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 17.75% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.16B USD | Price to earnings Ratio - | 1Y Target Price 68 |
Price to earnings Ratio - | 1Y Target Price 68 | ||
Volume (30-day avg) 2.5M shares | Beta 1.27 | 52 Weeks Range 32.27 - 68.98 | Updated Date 11/10/2026 |
52 Weeks Range 32.27 - 68.98 | Updated Date 11/10/2026 | ||
Dividends yield (FY) 0.08% | Basic EPS (TTM) -1.1 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Science Research | NMR, Mass Spectrometry, and Imaging tools for academic/pharma R&D. | Selling high-end tools to scientists. |
| Clinical Diagnostics | Microbiology and molecular diagnostics solutions for hospitals and clinics. | Providing equipment for medical testing. |
| Materials & Applied Analysis | Nano-analysis and X-ray systems for semiconductor and industrial use. | Enabling precision industrial testing. |
| Geography | Global sales across Americas, EMEA, and APAC. | Diversified global revenue streams. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 0.42 | Actual 0.56 |
Profitability
Profit Margin -3.51% | Operating Margin (TTM) 12.44% |
Management Effectiveness
Return on Assets (TTM) 3.28% | Return on Equity (TTM) -4.79% |
Valuation
Trailing PE - | Forward PE 13.83 | Enterprise Value 11.71B | Price to Sales(TTM) 2.89 |
Enterprise Value 11.71B | Price to Sales(TTM) 2.89 | ||
Enterprise Value to Revenue 3.11 | Enterprise Value to EBITDA 50.93 | Shares Outstanding 152.72M | Shares Floating 103.93M |
Shares Outstanding 152.72M | Shares Floating 103.93M | ||
Percent Insiders 26.97 | Percent Institutions 94.88 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.